U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C21H29NO2
Molecular Weight 327.4605
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of UR-144 N(4-HYDROXYPENTYL)

SMILES

CC(O)CCCN1C=C(C(=O)C2C(C)(C)C2(C)C)C3=C1C=CC=C3

InChI

InChIKey=YHFHYHZNLCEAAP-UHFFFAOYSA-N
InChI=1S/C21H29NO2/c1-14(23)9-8-12-22-13-16(15-10-6-7-11-17(15)22)18(24)19-20(2,3)21(19,4)5/h6-7,10-11,13-14,19,23H,8-9,12H2,1-5H3

HIDE SMILES / InChI

Molecular Formula C21H29NO2
Molecular Weight 327.4605
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

UR-144 N(4-hydroxypentyl) is a potent synthetic cannabinoid designed by Abbott Laboratories as a CB2 selective agonist for pain management. UR-144 N(4-hydroxypentyl) is a metabolite of another CB2-selective cannabinoid UR-144. Pre-clinical studies of nociceptive and neuropathic pain have shown that CB2-selective ligands are analgesics without causing the adverse side effects linked with CB1 receptor activation. However, nor UR-144 nor UR-144 N(4-hydroxypentyl) has no therapeutic application.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In Vitro Use Guide
Phoenix Amphotropic (AMPHO) cell line were washed twice with Opti-MEM I Reduced Serum Medium to remove any remaining FBS, and 100 μL of Opti-MEM I was added. The Nano-Glo Live Cell reagent (Promega), a nonlytic detection reagent containing the cell permeable furimazine substrate, was prepared by diluting the Nano-Glo Live Cell substrate 20× using Nano-Glo LCS Dilution buffer, and 25 μL was added to each well. Subsequently, the plate was placed in a luminometer, the GloMAX96 (Promega). Luminescence was monitored during the equilibration period until the signal stabilized (30−45 min). For agonist experiments, we added 10 μL per well of test compounds (UR-144 N-pentanoic acid), present as 13.5× stocks in 50% methanol in Opti-MEM I. The luminescence was continuously detected for 120 min. Solvent controls were run in all experiments; the final concentration of methanol (3.7%) did not pose a problem given the short readout time of the assay.
Substance Class Chemical
Record UNII
HOM2IB42C4
Record Status Validated (UNII)
Record Version